Synthesis of new


Journal

RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657

Informations de publication

Date de publication:
16 Apr 2020
Historique:
received: 22 11 2019
accepted: 24 03 2020
entrez: 2 5 2022
pubmed: 17 4 2020
medline: 17 4 2020
Statut: epublish

Résumé

The synthesis of new

Identifiants

pubmed: 35495460
doi: 10.1039/c9ra09783j
pii: c9ra09783j
pmc: PMC9052211
doi:

Types de publication

Journal Article

Langues

eng

Pagination

15116-15123

Informations de copyright

This journal is © The Royal Society of Chemistry.

Déclaration de conflit d'intérêts

There are no conflicts to declare.

Références

Mol Med Rep. 2014 Jan;9(1):83-90
pubmed: 24213221
Curr Med Chem. 2006;13(11):1337-57
pubmed: 16712474
Eur J Pharmacol. 2009 Dec 25;625(1-3):143-50
pubmed: 19836377
Eur J Med Chem. 2017 Dec 15;142:8-31
pubmed: 28442170
Adv Pharm Bull. 2019 Oct;9(4):674-684
pubmed: 31857974
Acta Crystallogr C Struct Chem. 2015 Jan;71(Pt 1):3-8
pubmed: 25567568
Ann Oncol. 2006 Dec;17(12):1826-9
pubmed: 16971664
Drug Des Devel Ther. 2017 Mar 03;11:599-616
pubmed: 28424538
Eur J Med Chem. 2010 Feb;45(2):471-5
pubmed: 19913953
Biometals. 2012 Feb;25(1):9-21
pubmed: 22002344
Eur J Med Chem. 2018 Oct 5;158:7-24
pubmed: 30199707
Indian J Clin Biochem. 2015 Jan;30(1):11-26
pubmed: 25646037
Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22
pubmed: 18156677
Inorg Chem. 2008 Jul 7;47(13):5591-600
pubmed: 18510287
J Inorg Biochem. 2011 Dec;105(12):1720-8
pubmed: 22104300
Chem Soc Rev. 2014 Jul 7;43(13):4751-77
pubmed: 24723061
Adv Pharm Bull. 2018 Jun;8(2):267-275
pubmed: 30023328
Cancer Chemother Pharmacol. 2008 Dec;63(1):127-38
pubmed: 18350297
Expert Opin Drug Metab Toxicol. 2013 Mar;9(3):333-47
pubmed: 23157726
Crit Rev Oncol Hematol. 2014 Jan;89(1):43-61
pubmed: 23972663
Molecules. 2018 Jan 12;23(1):
pubmed: 29329257
J Enzyme Inhib Med Chem. 2018 Dec;33(1):1006-1023
pubmed: 29862867
Curr Med Chem. 2017;24(15):1586-1606
pubmed: 27978798
Inorg Chem. 2006 Jun 26;45(13):5073-83
pubmed: 16780329
Front Pharmacol. 2018 Nov 13;9:1300
pubmed: 30483135
Mol Pharm. 2013 May 6;10(5):1964-76
pubmed: 23510087
Chem Soc Rev. 2013 Jan 7;42(1):202-24
pubmed: 23042411
Cancer Treat Rev. 2007 Feb;33(1):9-23
pubmed: 17084534

Auteurs

Vnira R Akhmetova (VR)

Institute of Petrochemistry and Catalysis, Russian Academy of Sciences 141 Prospekt Oktyabrya 450075 Ufa Russian Federation vnirara@mail.ru +7 3472 842750 +7 3472 842750.

Nail S Akhmadiev (NS)

Institute of Petrochemistry and Catalysis, Russian Academy of Sciences 141 Prospekt Oktyabrya 450075 Ufa Russian Federation vnirara@mail.ru +7 3472 842750 +7 3472 842750.

Marat F Abdullin (MF)

Ufa Institute of Chemistry, Russian Academy of Sciences 71 Prospekt Oktyabrya 450054 Ufa Russian Federation.

Lilya U Dzhemileva (LU)

Institute of Petrochemistry and Catalysis, Russian Academy of Sciences 141 Prospekt Oktyabrya 450075 Ufa Russian Federation vnirara@mail.ru +7 3472 842750 +7 3472 842750.

Vladimir A D'yakonov (VA)

Institute of Petrochemistry and Catalysis, Russian Academy of Sciences 141 Prospekt Oktyabrya 450075 Ufa Russian Federation vnirara@mail.ru +7 3472 842750 +7 3472 842750.

Classifications MeSH